press
October 21, 2021
Obsidian Therapeutics Appoints Maria Fardis, Ph.D., to Board of Directors Board expansion supports progression of engineered TIL therapies into clinical studies CAMBRIDGE, Mass., Oct. 21, 2021 […]
September 15, 2021
Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the European Society for Medical Oncology Congress 2021 CAMBRIDGE, Mass., September 15, 2021 – Obsidian Therapeutics, […]
September 9, 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing Funding to Advance Pipeline of Engineered TIL Therapies for Solid Tumors into Clinical Studies September 9, […]
May 4, 2021
Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the 24th American Society of Gene and Cell Therapy Annual Meeting May 4, 2021, 08:00 AM […]
April 22, 2021
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing April 22, 2021, 08:00 AM Eastern Time Multi-year strategic research collaboration leverages […]
November 18, 2020
Obsidian Therapeutics & MD Anderson announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors Nov. 18, 2020, 08:30 […]
September 17, 2020
Obsidian Therapeutics Appoints Jan ter Meulen, M.D., Ph.D., as Chief Scientific Officer Sept. 17, 2020, 08:00 AM Eastern Time CAMBRIDGE, Mass., Sept. 17, 2020 – Obsidian Therapeutics, Inc., […]
September 15, 2020
Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate Sept. 15, 2020, 07:30 AM Eastern Time CAMBRIDGE, Mass., Sept. 15, 2020 – Obsidian Therapeutics, Inc., […]
September 3, 2020
Obsidian Therapeutics Appoints Rob Ross, M.D., to Board of Directors Board expansion supports ongoing development of cytoDRiVE™ programs and external collaborations Sept. 3, 2020, 08:00 AM […]